Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

999512

registered interest
date	01/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Heroin: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will allocate funding to local authorities that plan to implement heroin assisted treatment.
tabling member constituency	Easington
tabling member printed	Grahame Morris
uin	187009
answer	answer is ministerial correction date of answer 06/11/2018 answer text <p>Local authorities are responsible for making decisions on how to spend their allocation of the public health grant based on the needs of their local population. Local authorities are responsible for commissioning drug treatment to meet those needs, including heroin assisted treatment services.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 06/11/2018 15:08:16 answering member 4067 label Biography information for Steve Brine
tabling member	3973 label Biography information for Grahame Morris

999628

registered interest
date	01/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Influenza: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 25 October 2018 to Question 183928 on Influenza: Vaccination, and with reference to the guidance, Flu Vaccination Programme Delivery Guidance 2018-19 published by NHS England, what assessment he has made of appropriateness of delivering aTIV to healthcare providers by mid-November.
tabling member constituency	Houghton and Sunderland South
tabling member printed	Bridget Phillipson
uin	187015
answer	answer is ministerial correction date of answer 06/11/2018 answer text <p>The adjuvanted trivalent flu vaccine is the recommended vaccine for those aged 65 years and over because it is a more effective vaccine for this age group and should offer better protection against flu compared to those previously used in the United Kingdom programme. This is explained in the Flu Vaccination Programme Delivery Guidance 2018-19 available at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/publication/flu-vaccination-programme-delivery-guidance-2018-19/" target="_blank">https://www.england.nhs.uk/publication/flu-vaccination-programme-delivery-guidance-2018-19/</a></p><p> </p><p>To ensure equitable access across the UK, deliveries of this vaccine are being phased between September and November. General practices and pharmacies were informed of the phased deliveries in April 2018 and given confirmed delivery dates in August. The supply to date has been on schedule.</p><p> </p><p>With appropriate planning, all eligible patients should be able to be offered vaccine before the flu season starts.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 06/11/2018 15:13:14 answering member 4067 label Biography information for Steve Brine
tabling member	4046 label Biography information for Bridget Phillipson

999155

registered interest
date	31/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Chronic Illnesses: Life Insurance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions he has had with the Chancellor of the Exchequer on life insurance policies for people suffering from (a) long term medical conditions and (b) muscular dystrophy; and if he will make a statement.
tabling member constituency	Gedling
tabling member printed	Vernon Coaker
uin	186179
answer	answer is ministerial correction date of answer 05/11/2018 answer text <p>My Rt. hon. Friend the Secretary of State for Health and Social Care meets Cabinet colleagues regularly to discuss a number of different issues.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 05/11/2018 15:39:18 answering member 4067 label Biography information for Steve Brine
tabling member	360 label Biography information for Lord Coaker

999270

registered interest
date	31/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Rehabilitation
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 24 October to Question 183290 on Rehabilitation, when the review of community performance reporting was commissioned; who is undertaking that review; and what the (a) terms of reference and (b) time frame are for that review.
tabling member constituency	North Norfolk
tabling member printed	Norman Lamb
uin	186241
answer	answer is ministerial correction date of answer 05/11/2018 answer text <p>There was no national data collection of the activity and outcomes of healthcare that takes place out of hospital, and so it was agreed via the National Information Board (NIB) and NHS England’s Data Co-ordination Group in 2016 to develop a community services dataset, which has had two distinct phases.</p><p> </p><p>The process that has been followed by NHS England is as follows.</p><p> </p><p>In the first phase, now completed, the Community Services Data Set (CSDS) was developed by removing the age cap from the Children and Young People’s Health Services dataset and has been collecting data since November 2017. NHS England continues to work with NHS Digital to encourage community service providers to complete their statutory obligations to submit data to improve the knowledge and information we have available nationally on services delivered locally.</p><p> </p><p>The CSDS will be further enhanced with a phase two development that will broaden the scope including outcome measures, and work is scheduled to begin on the scope shortly with plans to deliver in the autumn of 2020. Further work is also ongoing in NHS Digital to establish connectivity across national data sets to give longitudinal intelligence to support future planning processes.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 05/11/2018 15:30:27 answering member 4067 label Biography information for Steve Brine
tabling member	1439 label Biography information for Norman Lamb

999373

registered interest
date	31/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Rehabilitation
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 25 October 2018 to Question 180694 on Alcoholic Drinks: Rehabilitation, how many in-patient beds are commissioned for the treatment of substance misuse in (a) England, (b) London and (c) Suffolk.
tabling member constituency	Central Suffolk and North Ipswich
tabling member printed	Dr Dan Poulter
uin	186302
answer	answer is ministerial correction date of answer 05/11/2018 answer text <p>This data is not collected centrally.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 05/11/2018 15:28:53 answering member 4067 label Biography information for Steve Brine
tabling member	3932 label Biography information for Dr Dan Poulter

999389

registered interest
date	31/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Harvoni
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to reduce the cost to the NHS of Harvoni; and if he will make a statement.
tabling member constituency	Harrow West
tabling member printed	Gareth Thomas
uin	186163
answer	answer is ministerial correction date of answer 05/11/2018 answer text <p>We are informed by NHS England that in order to ensure the best use of public funds, the National Health Service has used the procurement process to ensure that optimal value for money is achieved when purchasing drugs, which are used in secondary care.</p><p> </p><p>The NHS is working to ensure consistent use of clinically-appropriate lowest acquisition cost drugs. This has encouraged competitive pricing in return for market share. This process has allowed for an increase in the number of patients being cured within the available resources, with in excess of 30,000 patients with hepatitis C treated so far. The NHS is currently undertaking a long-term strategic procurement to increase treatment and improve value further.</p><p> </p><p>NHS England’s Commercial Medicines Unit’s six-monthly tenders, together with innovative approaches which mean the NHS is given a refund if a course of treatment does not result in cure, have succeeded in delivering reduced price per patient for all direct acting antiviral Hepatitis C drugs, such as Harvoni (ledipasvir-sofosbuvir).</p><p> </p><p>The Department has made no such estimate of the number of patients recommended the drug Harvoni by medical practitioners who have been denied access on the grounds of affordability.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 186164 question first answered 05/11/2018 15:34:31 answering member 4067 label Biography information for Steve Brine
tabling member	177 label Biography information for Gareth Thomas

999392

registered interest
date	31/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Harvoni
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate he has made of the number of patients recommended the drug Harvoni by medical practitioners who have been denied access to the drug on grounds of affordability; and if he will make a statement.
tabling member constituency	Harrow West
tabling member printed	Gareth Thomas
uin	186164
answer	answer is ministerial correction date of answer 05/11/2018 answer text <p>We are informed by NHS England that in order to ensure the best use of public funds, the National Health Service has used the procurement process to ensure that optimal value for money is achieved when purchasing drugs, which are used in secondary care.</p><p> </p><p>The NHS is working to ensure consistent use of clinically-appropriate lowest acquisition cost drugs. This has encouraged competitive pricing in return for market share. This process has allowed for an increase in the number of patients being cured within the available resources, with in excess of 30,000 patients with hepatitis C treated so far. The NHS is currently undertaking a long-term strategic procurement to increase treatment and improve value further.</p><p> </p><p>NHS England’s Commercial Medicines Unit’s six-monthly tenders, together with innovative approaches which mean the NHS is given a refund if a course of treatment does not result in cure, have succeeded in delivering reduced price per patient for all direct acting antiviral Hepatitis C drugs, such as Harvoni (ledipasvir-sofosbuvir).</p><p> </p><p>The Department has made no such estimate of the number of patients recommended the drug Harvoni by medical practitioners who have been denied access on the grounds of affordability.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 186163 question first answered 05/11/2018 15:34:31 answering member 4067 label Biography information for Steve Brine
tabling member	177 label Biography information for Gareth Thomas

999408

registered interest
date	31/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Chronic Obstructive Pulmonary Disease
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 30 October 2018 to Question 183881 on chronic obstructive pulmonary disease, what steps he is taking to tackle the increase in the number of people diagnosed with that disease.
tabling member constituency	East Londonderry
tabling member printed	Mr Gregory Campbell
uin	186232
answer	answer is ministerial correction date of answer 05/11/2018 answer text <p>Improving care for people with lung disease is a key priority for the National Health Service.</p><p> </p><p>The NHS RightCare Chronic Obstructive Pulmonary Disease (COPD) pathway, is being rolled out nationally through clinical commissioning groups and defines the core components of an optimal service for people with COPD. The pathway provides a set of resources to support local health economies to address variation and improve population health.</p><p> </p><p>NHS England is also working with NHS Improvement, Public Health England and the third sector to ensure all components of the COPD pathway including, identification, diagnosis, treatment and management of respiratory conditions are coordinated across the health system.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 05/11/2018 15:24:40 answering member 4067 label Biography information for Steve Brine
tabling member	1409 label Biography information for Mr Gregory Campbell

997590

registered interest
date	30/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Influenza: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether all GP practices in the (a) Stroud constituency and (b) England have sufficient supplies of the FluMist flu vaccine to vaccinate all vulnerable groups including those eligible through age.
tabling member constituency	Stroud
tabling member printed	Dr David Drew
uin	185480
answer	answer is ministerial correction date of answer 05/11/2018 answer text <p>Public Health England (PHE) centrally procures flu vaccines for the children’s national flu immunisation programme, these being the nasal spray Fluenz Tetra supplied by AstraZeneca and a quadrivalent inactivated influenza vaccine supplied by Sanofi Pasteur. This programme provides influenza vaccination for children between the ages of two and 17 years of age. If the Fluenz Tetra nasal spray is unsuitable, children are offered the quadrivalent inactivated influenza vaccine as an alternative. Other vulnerable groups are offered alternative vaccines that are more effective in protecting them against influenza.</p><p> </p><p>Sufficient vaccine has been procured to ensure that all eligible children who present at general practices and schools for vaccination can be offered the appropriate vaccine. Stocks are carefully managed by PHE to ensure there is equitable distribution across England, including the Stroud constituency, and sufficient in-date vaccine for patients who present throughout the season.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 05/11/2018 15:33:22 answering member 4067 label Biography information for Steve Brine
tabling member	252 label Biography information for Dr David Drew

997640

registered interest
date	30/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Allergies: Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 9 October 2018 to Question 173542 on Allergies: Medical Treatments, what support his Department has provided to people affected by the national shortage of EpiPen 0.3mg auto-injectors.
tabling member constituency	East Dunbartonshire
tabling member printed	Jo Swinson
uin	185550
answer	answer is ministerial correction date of answer 05/11/2018 answer text <p>The Department is working very closely with all the manufacturers of adrenaline auto-injectors, the Medicines and Health products Regulatory Agency, and NHS England to improve the situation as quickly as possible. Supplies of EpiPen 0.3mg and the alternative adrenaline auto-injectors are currently available in volumes that are sufficient to meet normal United Kingdom requirements and further deliveries of all three brands of adrenaline autoinjectors are expected in the coming weeks. Comprehensive information and guidance, with input from National Health Service allergy experts has been cascaded to all healthcare professionals, schools, patient groups and frontline NHS services, which provides information about the supply issue, management options and advice to share with patients.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 185551 question first answered 05/11/2018 15:27:30 answering member 4067 label Biography information for Steve Brine
tabling member	1513 label Biography information for Jo Swinson